<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Trubion Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/trubion-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(TRBN) Trubion Pharmaceuticals Trims Size of Quarterly Loss</title>
		<link>http://www.stockbloghub.com/2010/08/23/trbn-trubion-pharmaceuticals-trims-size-of-quarterly-loss/48508</link>
		<comments>http://www.stockbloghub.com/2010/08/23/trbn-trubion-pharmaceuticals-trims-size-of-quarterly-loss/48508#comments</comments>
		<pubDate>Mon, 23 Aug 2010 14:15:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[EBS]]></category>
		<category><![CDATA[Emergent Biosolutions]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48508</guid>
		<description><![CDATA[Trubion Pharmaceuticals Inc. (TRBN) posted a loss of 28 cents per share during the second quarter of 2010, narrower than the Zacks Consensus Estimate for a loss of 34 cents and also narrower than the year-ago loss of 37 cents. Higher revenues earned during the quarter helped trim the loss. Quarter in Detail Quarterly revenues increased 39% year over year to $5.7 million, in line with the Zacks Consensus Estimate. Trubion Pharma recognized increased revenues under its partnership agreement with Abbott Laboratories (ABT) during the quarter, thereby boosting total revenues. Trubion Pharma records its entire revenue from collaboration agreements with Pfizer Inc. (PFE) and Abbott Labs. While the agreement with Pfizer is for the development of CD20-directed candidates including SBI-087 (rheumatoid arthritis and systemic lupus erythematosus), the deal with Abbott Labs is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/23/trbn-trubion-pharmaceuticals-trims-size-of-quarterly-loss/48508/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TRBN) Trubion Pharmaceuticals&#8217; Loss is Wider Than Expected</title>
		<link>http://www.stockbloghub.com/2010/03/23/trbn-trubion-pharmaceuticals-loss-is-wider-than-expected/31466</link>
		<comments>http://www.stockbloghub.com/2010/03/23/trbn-trubion-pharmaceuticals-loss-is-wider-than-expected/31466#comments</comments>
		<pubDate>Tue, 23 Mar 2010 17:54:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31466</guid>
		<description><![CDATA[Trubion Pharmaceuticals, Inc.’s (TRBN) fourth quarter fiscal 2009 net loss per share came in at 29 cents, wider than the Zacks Consensus Estimate by 10 cents. The year-ago loss was 36 cents. The year-over-year decline in loss for the reported quarter was attributable to higher revenues. Quarterly Results Revenue for the reported quarter came in at $5.2 million as against $4.3 million in the year-ago quarter, up 20.9%. Total operating expenses for the reported quarter decreased marginally to $10.4 million from $10.7 million in the year-ago quarter. The decrease was primarily attributable to lower outside manufacturing and laboratory expense. Research and development expenses for the reported quarter fell approximately 18.1% to $6.81 million. General and administrative costs for the reported quarter climbed approximately 52.1% year-over-year to $3.56 million. Yearly Results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/23/trbn-trubion-pharmaceuticals-loss-is-wider-than-expected/31466/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FACT) Facet Biotech Rejects Biogen Idec Again</title>
		<link>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636</link>
		<comments>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:27:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22636</guid>
		<description><![CDATA[Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech&#8217;s stockholders. Earlier this month, Biogen had come back with a revised offer of $17.50 per share (up from the previous offer of $14.50) and said that this is its “best and final&#8221; offer. The offer represents a 21% premium over the previous offer and a premium of approximately 98% over the closing price of Facet’s common stock on September 3, 2009, the day before Biogen announced its proposal to acquire all the outstanding shares of Facet. The offer is scheduled to expire at 12:00 midnight, New York City time, on Dec 16, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation</title>
		<link>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157</link>
		<comments>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:06:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18157</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech stock have been tendered. Earlier this month, Facet’s board of directors unanimously recommended that its stockholders should reject Biogen’s tender offer under which the company is seeking to acquire for $14.50 per share in cash. The board determined that the offer is inadequate and not in the best interests of the stockholders. As a reminder, Biogen launched a hostile bid in September to acquire Facet by taking its offer directly to Facet’s shareholders. The deal is valued at approximately $356 million. Biogen ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer</title>
		<link>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383</link>
		<comments>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383#comments</comments>
		<pubDate>Mon, 12 Oct 2009 17:02:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17383</guid>
		<description><![CDATA[In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet Biotech common stock for $14.50 per share in cash. The board has determined that the offer is inadequate and not in the best interests of the company’s stockholders. As a reminder, Biogen launched a hostile bid in September to acquire Facet for $14.50 per share by taking its offer directly to Facet’s shareholders. The deal is valued at approximately $356 million. Biogen had initially approached Facet with an offer of $15 per share on Aug 17, 2009. However, Facet did not accept the offer as the company doubted its benefit for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech</title>
		<link>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986</link>
		<comments>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:57:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15986</guid>
		<description><![CDATA[After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash balance is less than Biogen’s offer price. The deal is valued at approximately $356 million. The tender offer will expire at 12:00 midnight, ET, on Oct. 19, 2009. As a reminder, Biogen had initially approached Facet with an offer of $15 per share on Aug. 17, 2009. However, Facet did not accept the offer as the company believed that it was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Maintains Facet Biotech Offer</title>
		<link>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795</link>
		<comments>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795#comments</comments>
		<pubDate>Thu, 10 Sep 2009 02:38:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14795</guid>
		<description><![CDATA[Yesterday, Biogen Idec (BIIB) reiterated its intention to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, even though Facet turned down the offer saying it was not in the best interests of its shareholders. The offer price represents a 64% premium to Facet’s closing price on September 3, 2009. The deal is valued at approximately $356 million. Biogen had initially approached Facet with an offer of $15 per share on August 17, 2009. However, Facet did not accept the offer as the company believed that the offer price was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. According to Biogen, the Trubion deal led to a reduction in Facet’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TRBN) Trubion Pharmaceuticals &amp; Facet Biotech to Jointly Develop and Market Leukemia Drug</title>
		<link>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953</link>
		<comments>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953#comments</comments>
		<pubDate>Mon, 31 Aug 2009 21:08:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals]]></category>
		<category><![CDATA[SPPI]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13953</guid>
		<description><![CDATA[On Friday, Trubion Pharmaceuticals, Inc. (TRBN) agreed to jointly develop and commercialize TRU-016 globally with Facet Biotech Corp. (FACT).  TRU-016 is undergoing early-stage studies for chronic lymphocytic leukemia (CLL). The deal requires Facet to make a $20 million upfront payment to Trubion coupled with an additional $176.5 million on the achievement of certain milestones. Further, Facet has agreed to buy 2.24 million shares of newly issued Trubion common stock for $10 million. The companies have agreed to contribute equally towards costs related to development, commercialization and promotional activities. All global operating profits will be shared equally. The TRU-016 program is focused on the development of a novel CD37-targeted therapy for B-cell malignancies, such as Non-Hodgkin&#8217;s lymphoma (NHL) and CLL. CD37 is a clinically validated target for the treatment of B-cell ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

